Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine

Biological Psychiatry

Volumn 83, Issue 1, 2018, Pages 29-37

  Ghosal, Sriparna ^a   Bang, Eunyoung ^a   Yue, Wenzhu ^a   Hare, Brendan D ^a   Lepack, Ashley E ^a   Girgenti, Matthew J ^a   Duman, Ronald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; mTORC1; Muscarinic receptor; Prefrontal cortex; TrkB receptor; Voltage dependent calcium channel

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SCOPOLAMINE; TROPOMYOSIN; VERAPAMIL; 4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL L TYPE; MUSCARINIC M1 RECEPTOR; SCOPOLAMINE BROMIDE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN CELL CULTURE; CANNULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIM TEST; IN VITRO STUDY; IN VIVO STUDY; MALE; MAPK SIGNALING; MOUSE; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL CULTURE; DEPRESSION; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; SPRAGUE DAWLEY RAT; SYNAPTOSOME; TIME FACTOR; TRANSGENIC MOUSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNELS, L-TYPE; CELLS, CULTURED; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GAMMA-AMINOBUTYRIC ACID; MALE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RECEPTOR, TRKB; SCOPOLAMINE HYDROBROMIDE; SYNAPTOSOMES; TIME FACTORS; VERAPAMIL;

EID: 85025467627     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2017.06.017     Document Type: Article

References (41)

1. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003), 3095–3105.
2. Fournier, J.C., DeRubeis, R.J., Hollon, S.D., Dimidjian, S., Amsterdam, J.D., Shelton, R.C., et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 303 (2010), 47–53.
3. Papakostas, G.I., Limitations of contemporary antidepressants: Tolerability. J Clin Psychiatry 68:Suppl 10 (2007), 11–17.
4. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
5. Furey, M.L., Drevets, W.C., Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63 (2006), 1121–1129.
6. Voleti, B., Navarria, A., Liu, R.J., Banasr, M., Li, N., Terwilliger, R., et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74 (2013), 742–749.
7. Navarria, A., Wohleb, E.S., Voleti, B., Ota, K.T., Dutheil, S., Lepack, A.E., et al. Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis 82 (2015), 254–261.
8. Wohleb, E.S., Wu, M., Gerhard, D.M., Taylor, S.R., Picciotto, M.R., Alreja, M., et al. GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest 126 (2016), 2482–2494.
9. Duman, R.S., Aghajanian, G.K., Sanacora, G., Krystal, J.H., Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 22 (2016), 238–249.
10. Moghaddam, B., Adams, B., Verma, A., Daly, D., Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17 (1997), 2921–2927.
11. Duman, R.S., Aghajanian, G.K., Neurobiology of rapid acting antidepressants: Role of BDNF and GSK-3β. Neuropsychopharmacology, 39, 2014, 233.
12. Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
13. Liu, R.J., Lee, F.S., Li, X.Y., Bambico, F., Duman, R.S., Aghajanian, G.K., Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 71 (2012), 996–1005.
14. Chen, Z.Y., Jing, D., Bath, K.G., Ieraci, A., Khan, T., Siao, C.J., et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314 (2006), 140–143.
15. Egan, M.F., Kojima, M., Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A., et al. The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 (2003), 257–269.
16. Lepack, A.E., Fuchikami, M., Dwyer, J.M., Banasr, M., Duman, R.S., BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol, 18, 2015, pyu033.
17. Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72 (2012), e27–e28.
18. Lepack, A.E., Bang, E., Lee, B., Dwyer, J.M., Duman, R.S., Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. Neuropharmacology 111 (2016), 242–252.
19. Cazorla, M., Premont, J., Mann, A., Girard, N., Kellendonk, C., Rognan, D., Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 121 (2011), 1846–1857.
20. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
21. Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., et al. R-Ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry, 5, 2015, e632.
22. Dwyer, J.M., Maldonado-Aviles, J.G., Lepack, A.E., DiLeone, R.J., Duman, R.S., Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior. Proc Natl Acad Sci U S A 112 (2015), 6188–6193.
23. Borroni, A.M., Fichtenholtz, H., Woodside, B.L., Teyler, T.J., Role of voltage-dependent calcium channel long-term potentiation (LTP) and NMDA LTP in spatial memory. J Neurosci 20 (2000), 9272–9276.
24. Jourdi, H., Hsu, Y.T., Zhou, M., Qin, Q., Bi, X., Baudry, M., Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci 29 (2009), 8688–8697.
25. Witkin, J.M., Overshiner, C., Li, X., Catlow, J.T., Wishart, G.N., Schober, D.A., et al. M1 and M2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J Pharmacol Exp Ther 351 (2014), 448–456.
26. Sheffler, D.J., Williams, R., Bridges, T.M., Xiang, Z., Kane, A.S., Byun, N.E., et al. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol 76 (2009), 356–368.
27. Kato-Negishi, M., Muramoto, K., Kawahara, M., Kuroda, Y., Ichikawa, M., Developmental changes of GABAergic synapses formed between primary cultured cortical neurons. Brain Res Dev Brain Res 152 (2004), 99–108.
28. Weir, K., Blanquie, O., Kilb, W., Luhmann, H., Sinning, A., Comparison of spike parameters from optically identified GABAergic and glutamatergic neurons in sparse cortical cultures. Front Cell Neurosci, 8, 2015, 460.
29. A receptor calcium elevations in developing hypothalamic neurons. J Neurophysiol 79 (1998), 1360–1370.
30. Golding, J.F., Stott, J.R., Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br J Clin Pharmacol 43 (1997), 633–637.
31. Xiang, Z., Thompson, A.D., Jones, C.K., Lindsley, C.W., Conn, P.J., Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. J Pharmacol Exp Ther 340 (2012), 595–603.
32. Roldan, G., Bolanos-Badillo, E., Gonzalez-Sanchez, H., Quirarte, G.L., Prado-Alcala, R.A., Selective M1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats. Neurosci Lett 230 (1997), 93–96.
33. Kasashima, S., Kawashima, A., Muroishi, Y., Futakuchi, H., Nakanishi, I., Oda, Y., Neurons with choline acetyltransferase immunoreactivity and mRNA are present in the human cerebral cortex. Histochem Cell Biol 111 (1999), 197–207.
34. Lewis, D.A., Distribution of choline acetyltransferase-immunoreactive axons in monkey frontal cortex. Neuroscience 40 (1991), 363–374.
35. Mechawar, N., Descarries, L., The cholinergic innervation develops early and rapidly in the rat cerebral cortex: A quantitative immunocytochemical study. Neuroscience 108 (2001), 555–567.
36. Kosaka, T., Tauchi, M., Dahl, J., Cholinergic neurons containing GABA-like and/or glutamic acid decarboxylase-like immunoreactivities in various brain regions of the rat. Exp Brain Res 70 (1988), 605–617.
37. Kawaguchi, Y., Selective cholinergic modulation of cortical GABAergic cell subtypes. J Neurophysiol 78 (1997), 1743–1747.
38. Neske, G.T., Patrick, S.L., Connors, B.W., Contributions of diverse excitatory and inhibitory neurons to recurrent network activity in cerebral cortex. J Neurosci 35 (2015), 1089–1105.
39. Tripp, A., Oh, H., Guilloux, J.P., Martinowich, K., Lewis, D.A., Sibille, E., Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry 169 (2012), 1194–1202.
40. Drevets, W.C., Price, J.L., Furey, M.L., Brain structural and functional abnormalities in mood disorders: Implications for neurocircuitry models of depression. Brain Struct Funct 213 (2008), 93–118.
41. Harward, S.C., Hedrick, N.G., Hall, C.E., Parra-Bueno, P., Milner, T.A., Pan, E.H., et al. Autocrine BDNF–TrkB signalling within a single dendritic spine. Nature 538 (2016), 99–103.